B Cells, Be Gone — B-Cell Depletion in the Treatment of Rheumatoid Arthritis
Author:
- 17 June 2004
- journal article
- editorial
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 350 (25) , 2546-2548
Abstract
CD20 protein is expressed on the surface membrane of pre-B lymphocytes and mature B lymphocytes. The protein is located in the B-cell membrane, with 44 amino acids exposed in the extracellular space. Rituximab is a chimeric anti-CD20 antibody whose variable (antigen-binding) region was derived from a mouse antibody so that it has high affinity for CD20. The binding of rituximab to the CD20 antigen interferes with the activation and differentiation of B cells.1 Hematopoietic stem cells, pro-B lymphocytes, and plasma cells do not express CD20. This distribution permits the specific elimination of B cells without preventing the regeneration of B . . .Keywords
This publication has 4 references indexed in Scilit:
- Efficacy of B-Cell–Targeted Therapy with Rituximab in Patients with Rheumatoid ArthritisNew England Journal of Medicine, 2004
- Rituximab therapy and autoimmune disorders: Prospects for anti–B cell therapyArthritis & Rheumatism, 2003
- Therapeutic strategies for rheumatoid arthritisNature Reviews Drug Discovery, 2003
- From T to B and back again: positive feedback in systemic autoimmune diseaseNature Reviews Immunology, 2001